|
75
|
297
|
5angA |
Crystal structure of cdk2 in complex with 7-hydroxy-4-(morpholinomethyl)chromen-2-one processed with the crystaldirect automated mounting and cryo-cooling technology |
|
81
|
264
|
5drdA |
Aurora a kinase in complex with atp in space group p6122 |
|
78
|
293
|
5andA |
Crystal structure of cdk2 in complex with 2-imidazol-1-yl-1h- benzimidazole processed with the crystaldirect automated mounting and cryo-cooling technology |
|
82
|
264
|
5dt3A |
Aurora a kinase in complex with atp in space group p6122 |
|
82
|
264
|
5dr9A |
Aurora a kinase in complex with aa29 and jnj-7706621 in space group p6122 |
|
69
|
258
|
5dyjA |
Mysosin heavy chain kinase a catalytic domain mutant - d663a |
|
85
|
296
|
5anjA |
Crystal structure of cdk2 in complex with n-(9h-purin-6-yl)thiophene- 2-carboxamide processed with the crystaldirect automated mounting and cryo-cooling technology |
|
84
|
273
|
5drbA |
Crystal structure of wnk1 in complex with wnk463 |
|
84
|
298
|
5aneA |
Crystal structure of cdk2 in complex with 6-methoxy-7h-purine processed with the crystaldirect automated mounting and cryo-cooling technology |
|
81
|
274
|
5dwrA |
Identification of n-(4-((1r,3s,5s)-3-amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (pim447), a potent and selective proviral insertion site of moloney murine leukemia (pim) 1,2 and 3 kinase inhibitor in clinical trials for hematological malignancies |
|
85
|
265
|
5dnrA |
Aurora a kinase in complex with atp in space group p41212 |
|
78
|
265
|
5dlsA |
Identification of novel, in vivo active chk1 inhibitors utilizing structure guided drug design |
|
76
|
301
|
5dbxA |
Crystal structure of murine spak(t243d) in complex with amppnp |
|
90
|
307
|
5am7A |
Fgfr1 mutant with an inhibitor |
|
79
|
273
|
5diaA |
Pim1 in complex with cpd36 ((1s,3s)-n1-(6-(5-(pyridin-3-yl)-1h-pyrazolo[3,4-c]pyridin-3-yl)pyridin-2-yl)cyclohexane-1,3-diamine) |
|
83
|
264
|
5dosA |
Aurora a kinase in complex with aa35 and atp in space group p6122 |
|
87
|
281
|
5de2A |
Structural mechanism of nek7 activation by nek9-induced dimerisation |
|
80
|
273
|
5dgzA |
Discovery of 3,5-substituted 6-azaindazoles as potent pan-pim inhibitors |
|
89
|
264
|
5da3A |
Crystal structure of ptk6 kinase domain with inhibitor |
|
92
|
317
|
5d41A |
Egfr kinase domain in complex with mutant selective allosteric inhibitor |
|
84
|
265
|
5dn3A |
Aurora a in complex with atp and aa35. |
|
83
|
273
|
5dhjA |
Pim1 in complex with cpd4 (3-methyl-5-(pyridin-3-yl)-1h-pyrazolo[3,4-c]pyridine) |
|
85
|
309
|
5am6A |
Native fgfr1 with an inhibitor |
|
94
|
295
|
5deyA |
Crystal structure of pak1 in complex with an inhibitor compound g-5555 |
|
86
|
269
|
4zogA |
Vx-680/mk-0457 binds to human abl1 also in inactive dfg conformations. |
|
97
|
293
|
5dfpA |
Crystal structure of pak1 in complex with an inhibitor compound frax1036 |
|
89
|
268
|
5d7vA |
Crystal structure of ptk6 kinase domain |
|
84
|
297
|
5di1A |
Map4k4 in complex with an inhibitor |
|
100
|
295
|
5dewA |
Crystal structure of pak1 in complex with an inhibitor compound 5 |
|
88
|
300
|
5d7aA |
Crystal structure of the kinase domain of traf2 and nck-interacting protein kinase with ncb-0846 |
|
88
|
297
|
5dg5A |
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-met in complex with altiratinib analog dp-4157 |
|
76
|
289
|
5dh3A |
Crystal structure of mst2 in complex with xmu-mp-1 |
|
79
|
299
|
5d9hA |
Crystal structure of spak (stk39) dimer in the basal activity state |
|
110
|
324
|
5cshA |
Crystal structure of ck2alpha with compound 4 bound |
|
80
|
289
|
5ajqA |
Human lok (stk10) in complex with bosutinib |
|
113
|
328
|
5cu2A |
Crystal structure of ck2alpha with 2-hydroxy-5-methylbenzoic acid and (methyl 4-((3-(3-chloro-4-(phenyl)benzylamino)propyl)amino)-4-oxobutanoat bound |
|
59
|
277
|
5d12A |
Kinase domain of csrc in complex with rl40 |
|
110
|
327
|
5csvA |
Crystal structure of ck2alpha with compound 6 bound |
|
101
|
358
|
5airA |
Structural analysis of mouse gsk3beta fused with lrp6 peptide. |
|
120
|
347
|
4yljA |
Crystal structure of dyrk1a in complex with 10-iodo-substituted 11h-indolo[3,2-c]quinoline-6-carboxylic acid inhibitor 5j |
|
116
|
348
|
5aikA |
Human dyrk1a in complex with ldn-211898 |
|
84
|
297
|
5cwzA |
Crystal structure of the kinase domain of human traf2 and nck-interacting protein kinase |
|
92
|
294
|
4ypdA |
Crystal structure of dapk1 catalytic domain in complex with the hinge binding fragment 4-methylpyridazine |
|
116
|
325
|
5cu3A |
Crystal structure of ck2alpha with compound 10 bound |
|
112
|
327
|
5cu4A |
Crystal structure of ck2alpha with compound 10 bound |
|
64
|
276
|
5d10A |
Kinase domain of csrc in complex with rl236 |
|
84
|
274
|
4yznA |
Humanized roco4 bound to compound 19 |
|
99
|
323
|
5cziA |
Egfr l858r mutant in complex with a shc peptide substrate |
|
101
|
328
|
5cquA |
Monoclinic complex structure of protein kinase ck2 catalytic subunit with a benzotriazole-based inhibitor generated by click-chemistry |
|
101
|
289
|
4ythA |
Discovery of vx-509 (decernotinib): a potent and selective janus kinase (jak) 3 inhibitor for the treatment of autoimmune diseases |
